Affymetrix Inc., a leading name in the biotechnology industry, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1992, the company has pioneered advancements in microarray technology, significantly impacting genomics and personalised medicine. Affymetrix is renowned for its innovative products, including GeneChip® microarrays and the Axiom® genotyping platform, which offer unparalleled accuracy and scalability for genetic analysis. These core services enable researchers to conduct high-throughput genomic studies, making Affymetrix a preferred choice among scientists and institutions worldwide. With a strong market position, Affymetrix has achieved numerous milestones, including collaborations with leading research organisations and contributions to significant scientific discoveries, solidifying its reputation as a key player in the life sciences sector.
How does Affymetrix Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Affymetrix Inc.'s score of 94 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Affymetrix Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Thermo Fisher Scientific Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. Affymetrix Inc. does not have documented reduction targets or specific climate pledges. However, it is important to note that the climate initiatives and performance metrics may be influenced by the sustainability strategies of Thermo Fisher Scientific Inc., which operates at a cascade level of 4 in relation to Affymetrix. As a subsidiary, Affymetrix may align with the broader climate commitments and targets set by Thermo Fisher Scientific, which are likely to include industry-standard practices for reducing greenhouse gas emissions across various scopes. However, without specific data or targets from Affymetrix itself, a detailed assessment of its individual climate commitments remains unavailable.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
Affymetrix Inc.'s Scope 3 emissions, which decreased by 26% last year and decreased by approximately 37% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 58% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Affymetrix Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.